NEWSROOM

MEDIA CONTACTS

 

media@galderma.com

Christian Marcoux, Chief Communications Officer: +41 76 315 26 50

Sébastien Cros, Corporate Communications Director: +41 79 529 59 85 

Filter news by date

6 . 22 . 2022

Galderma announces positive data from phase III trial, demonstrating efficacy and safety of nemolizumab in patients with prurigo nodularis

6 . 10 . 2022

 

Galderma announces positive results in two phase III studies for a novel liquid formulation botulinumtoxinA (RelabotulinumtoxinA) for the treatment of glabellar lines (frown) and lateral canthal lines (crow’s feet)

6 . 8 . 2022

 

Galderma to present new findings from innovative product portfolio at the 2022 VCS Annual Symposium

5 . 31 . 2022

 

Galderma to present extensive new clinical data across its portfolio of neuromodulators, fillers and biostimulators at the IMCAS World Congress 2022

4 . 6 . 2022

 

Cetaphil® debuts global sensitive skin awareness initiative

4 . 4 . 2022

 

Galderma launches a virtual experience this Rosacea Awareness Month showcasing how the condition goes beyond the visible with Rosacea Space

3 . 28 . 2022

 

Galderma to present new clinical data and high patient satisfaction across their portfolio of dermal fillers, collagen biostimulators and liquid neuromodulators at AMWC 2022

3 . 25 . 2022

 

Galderma to highlight latest science and innovation across its product portfolio at the 2022 AAD Annual meeting

2 . 22 . 2022

 

Taro to acquire Alchemee from Galderma

2 . 18 . 2022

 

Karen L. Ling joins Galderma’s Advisory Committee

2 . 14 . 2022

 

Galderma launches Alastin Skincare® ReFORM & RePAIR COMPLEX with TriHex Technology® designed to assist with recovery from surgical body procedures

1 . 5 . 2022

 

Galderma successfully completes acquisition of ALASTIN Skincare®

12 . 14 . 2021

 

Addressing gaps in acne management: New expert recommendations to optimize patient care